September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Topical 1% 5-Fluoruracil as a sole treatment of corneo-conjunctival ocular surface squamous neoplasia: long term results.
Author Affiliations & Notes
  • Giulia Midena
    GB Bietti Foundation, IRCCS, Roma, Italy
  • Raffaele Parrozzani
    GB Bietti Foundation, IRCCS, Roma, Italy
  • Luisa Frizziero
    Department of Ophthalmology, University of Padova, Padova, Italy
  • ilaria testi
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Edoardo Midena
    GB Bietti Foundation, IRCCS, Roma, Italy
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Footnotes
    Commercial Relationships   Giulia Midena, None; Raffaele Parrozzani, None; Luisa Frizziero, None; ilaria testi, None; Edoardo Midena, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2413. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giulia Midena, Raffaele Parrozzani, Luisa Frizziero, ilaria testi, Edoardo Midena; Topical 1% 5-Fluoruracil as a sole treatment of corneo-conjunctival ocular surface squamous neoplasia: long term results.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2413.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report, on a very long term, the clinical outcome of topical 1% 5-Fluorouracil (5 FU) used as sole treatment of ocular surface squamous neoplasia (OSSN).

Methods : Forty-five eyes of 45 patients affected by OSSN were included in this prospective study. Each patient underwent at baseline: full ophthalmologic examination, cytologic/histologic confirmation of clinical diagnosis, corneal/conjunctival confocal microscopy. Patients were initially treated with topical 1% 5FU four times a day for four weeks (one course). Adjunctive courses were used after at least one month free of therapy. Clinical resolution was confirmed by scraping cytology. Follow-up was performed monthly during therapy, and then after 1,3 and 6 months, and every 6 months thereafter. Ocular side effects were prospectively recorded.

Results : Cyto/histological diagnosis resulted in: low grade dysplasia in 20 cases (49%), high grade dysplasia in 13 cases (31%) and squamous cell carcinoma in 8 cases (19%). Mean follow-up was 105 ± 32 months (range 60 to 171 months). Complete tumor regression was achieved in 34 cases (83%), after a mean of 1.5 courses (range: 1-3 courses). Univariate analysis revealed that complete response was significantly related to: tumor thickness < 1.5 mm (p=0.005), lack of fornix or tarsal involvement (p=0.015 and 0.0002, respectively), and morphologic classification (p=0.028). Multivariate analysis showed that tumor thickness > 1.5 mm and multifocality were correlated with incomplete tumor response (p=0.045 and 0.023, respectively). Transient and reversible low to mild local side effects were documented in 19 (48%) treated eyes. All these side effects completely resolved in 4 weeks after treatment.

Conclusions : Topical 1% 5 FU eyedrops used as sole treatment of OSSN may be an effective and safe treatement, even on a very long term basis. Tumor thickness is the main limiting factor for complete success. This confirms that 1% topical 5 FU can be used at least as debulking procedure for all OSSN.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×